Crossmark

Ruxolitinib-loaded poly-ɛ-caprolactone (PCL) nanoparticles inhibit JAK2/STAT5 signaling in BT474 breast cancer cells by downregulating Bcl-2 and Mcl-1

Crossref DOI link: https://doi.org/10.1007/s11033-024-09764-3

Published Online: 2024-07-22

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Celik, Esin Guvenir

Eroglu, Onur
Funding

Funding for this research was provided by:

Bilecik Seyh Edebali University (2018-02. BŞEÜ.01-01)

Bilecik Seyh Edebali University (2018-02. BŞEÜ.01-01)
License Information

Text and Data Mining valid from 2024-07-22

Version of Record valid from 2024-07-22
More Information

Article History

Received: 18 April 2024

Accepted: 27 June 2024

First Online: 22 July 2024

Declarations

:

: We declare that the research presented in this article used a commercially available cell line and did not involve human participants or animals.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below